Exagen (NASDAQ:XGN – Get Free Report) posted its quarterly earnings data on Tuesday. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.02, Zacks reports. The business had revenue of $12.51 million during the quarter, compared to the consensus estimate of $13.55 million. Exagen had a negative net margin of 30.36% and a negative return on equity of 84.26%. During the same period in the prior year, the firm earned ($0.31) EPS. Exagen updated its FY 2024 guidance to EPS.
Exagen Trading Down 1.4 %
Shares of XGN stock opened at $2.75 on Thursday. Exagen has a 1 year low of $1.30 and a 1 year high of $3.71. The firm’s fifty day simple moving average is $2.84 and its 200 day simple moving average is $2.37. The company has a quick ratio of 4.32, a current ratio of 4.32 and a debt-to-equity ratio of 1.13.
Analyst Ratings Changes
Separately, William Blair reiterated an “outperform” rating on shares of Exagen in a research note on Wednesday.
Exagen Company Profile
Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).
Read More
- Five stocks we like better than Exagen
- What is the Dow Jones Industrial Average (DJIA)?
- Can United States Cellular Ride Higher on Its Spectrum Strategy?
- Low PE Growth Stocks: Unlocking Investment Opportunities
- HubSpot’s Growth in CRM: Can It Compete With Salesforce?
- Why Invest in 5G? How to Invest in 5G Stocks
- Neurogene Stock Plummets 44%: Is All Hope Lost for This Biotech?”
Receive News & Ratings for Exagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exagen and related companies with MarketBeat.com's FREE daily email newsletter.
